Development of secondary leukemia associated with (1;7)(q10;p10) in a patient with Crow-Fukase syndrome.
A 42-year-old woman with Crow-Fukase syndrome developed acute myeloid leukemia (M6: FAB classification) following treatment with alkylating agents (a total of 2,500 mg of melphalan and 9,800 mg of cyclophosphamide). Chromosome analysis of the bone marrow showed 49,XX,der(1;7)(q10;p10), +8, +19, +21 in therapy-related myelodysplastic syndrome with additional chromosomes 8, and 12 and two additional chromosomes 21 in acute leukemia. Because of the risk of therapy-related leukemia, alkylating agents should be used with caution in the treatment of Crow-Fukase syndrome.
Satoh
K
K
Department of Internal Medicine, Honma Hospital, Sakata.
Miura
I
I
Chubachi
A
A
Utsumi
S
S
Imai
H
H
Miura
A B
AB
D000328:Adult; D000477:Alkylating Agents / Q000009:adverse effects; D002869:Chromosome Aberrations; D002878:Chromosomes, Human, Pair 1; D002897:Chromosomes, Human, Pair 7; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000209:etiology* / Q000235:genetics*; D008558:Melphalan / Q000009:adverse effects; D009190:Myelodysplastic Syndromes / Q000209:etiology / Q000235:genetics; D016878:POEMS Syndrome / Q000150:complications*; D014178:Translocation, Genetic; D014314:Trisomy
D000477:Alkylating Agents; D003520:Cyclophosphamide; D008558:Melphalan